Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 3

ALEXION PHARMACEUTICALS INC

Form 3

February 12, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person *

Thiel Carsten

(Last)

1. Title of Security

(Instr. 4)

(First)

(Middle)

Statement

(Month/Day/Year)

02/02/2015

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

ALEXION PHARMACEUTICALS INC [ALXN]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O ALEXION PHARMACEUTICALS, INC.. 352 KNOTTER DRIVE

(Street)

Director _X__ Officer

10% Owner Other

6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) SVP, EMEA & Asia Pacific _X_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

CHESHIRE. CTÂ 06410

(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities

Beneficially Owned

3. Ownership 4. Nature of Indirect Beneficial

Ownership Form:

Direct (D) or Indirect (Instr. 5)

(I) (Instr. 5)

Common Stock, par value \$.0001 per share

 $26,000^{(1)}$

(Instr. 4)

Â D

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security 2. Date Exercisable and (Instr. 4)

Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4. Conversion or Exercise

5. Ownership Form of Ownership (Instr. 5)

6. Nature of Indirect Beneficial

Price of Derivative Derivative Security:

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Option to Purchase Common Stock	09/09/2015	09/09/2024	Common Stock, par value \$.0001 per share	30,000 (2)	\$ 161.37	D	Â

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Thiel Carsten

C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE. CTÂ 06410

Â SVP, EMEA & Asia Pacific

Â

Signatures

/s/ Michael Greco, Attorney-in-Fact for Carsten
Thiel

02/12/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Restricted stock units awarded under Amended and Restated 2004 Incentive Plan. These restricted stock units were awarded on
- (1) September 9, 2014. 14,000 vest on September 9, 2015 and 4,000 on the anniversary thereof until fully vested after four years from the grant date.
- Stock options awarded under Amended and Restated 2004 Incentive Plan. These stock options vest 7,500 on September 9, 2015, and 1,875 every three months thereafter until fully vested over 4 years from the grant date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2